Liothyronine
- Generic Name
- Liothyronine
- Brand Names
- Cytomel, Np Thyroid
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12I3NO4
- CAS Number
- 6893-02-3
- Unique Ingredient Identifier
- 06LU7C9H1V
- Background
Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.
- Indication
Liothyronine is officially approved for the following indications:
In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.
...
- Associated Conditions
- Autonomy of thyroid gland, Hyperthyroidism, Hypothyroidism, Myxedema coma, Thyroid Cancer, Euthyroid Goitre, Myxedema pre-coma
- Associated Therapies
- Supplemental or replacement therapy
Thyroid Hormone Supplementation in Patients With Septic Shock
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Cantonal Hospital Zenica
- Target Recruit Count
- 108
- Registration Number
- NCT05270798
- Locations
- 🇧🇦
Cantonal Hospital, Zenica, Bosnia and Herzegovina
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Emory University
- Registration Number
- NCT05017610
Energy Metabolism in Thyroidectomized Patients
- Conditions
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 13
- Registration Number
- NCT04782856
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 62
- Registration Number
- NCT04743661
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Developing Oral LT3 Therapy for Heart Failure - HFpEF
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 28
- Registration Number
- NCT04111536
- Locations
- 🇺🇸
Penn Medicine, Philadelphia, Pennsylvania, United States
Identification of Non-responders to Levothyroxine Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT03627611
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Effects of Liothyronine on Energy Expenditure and Cardiovascular Function
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 22
- Registration Number
- NCT03098433
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients
- Conditions
- Interventions
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Azienda USL Modena
- Target Recruit Count
- 160
- Registration Number
- NCT03053115
- Locations
- 🇮🇹
AziendaUSLModena, Modena, Italy
Open-label Study of Liothyronine in MS
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT02506751
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2019-12-05
- Target Recruit Count
- 7
- Registration Number
- NCT02457897
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.